Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA.
JAMA. 2010 Jan 13;303(2):137-43. doi: 10.1001/jama.2009.1987.
With the exception of the American Recovery and Reinvestment Act, funding support for biomedical research in the United States has slowed after a decade of doubling. However, the extent and scope of slowing are largely unknown.
To quantify funding of biomedical research in the United States from 2003 to 2008.
Publicly available data were used to quantify funding from government (federal, state, and local), private, and industry sources. Regression models were used to compare financial trends between 1994-2003 and 2003-2007. The numbers of new drug and device approvals by the US Food and Drug Administration over the same period were also evaluated.
Funding and growth rates by source; numbers of US Food and Drug Administration approvals.
Biomedical research funding increased from $75.5 billion in 2003 to $101.1 billion in 2007. In 2008, funding from the National Institutes of Health and industry totaled $88.8 billion. In 2007, funding from these sources, adjusted for inflation, was $90.2 billion. Adjusted for inflation, funding from 2003 to 2007 increased by 14%, for a compound annual growth rate of 3.4%. By comparison, funding from 1994 to 2003 increased at an annual rate of 7.8% (P < .001). In 2007, industry (58%) was the largest funder, followed by the federal government (33%). Modest increase in funding was not accompanied by an increase in approvals for drugs or devices. In 2007, the United States spent an estimated 4.5% of its total health expenditures on biomedical research and 0.1% on health services research.
After a decade of doubling, the rate of increase in biomedical research funding slowed from 2003 to 2007, and after adjustment for inflation, the absolute level of funding from the National Institutes of Health and industry appears to have decreased by 2% in 2008.
除了美国复苏与再投资法案外，美国的生物医学研究资金支持在经历了十年的翻番后有所放缓。然而，资金放缓的程度和范围在很大程度上是未知的。
量化 2003 年至 2008 年美国生物医学研究的资金情况。
利用公开数据来量化来自政府（联邦、州和地方）、私人和工业来源的资金。回归模型用于比较 1994-2003 年和 2003-2007 年的财务趋势。同期美国食品和药物管理局批准的新药和新器械数量也进行了评估。
按来源划分的资金和增长率；美国食品和药物管理局批准的数量。
2003 年至 2007 年，生物医学研究资金从 755 亿美元增加到 1011 亿美元。2008 年，国立卫生研究院和工业界的资金总计 888 亿美元。按通胀调整后，2007 年这些来源的资金为 902 亿美元。按通胀调整后，2003 年至 2007 年的资金增长了 14%，复合年增长率为 3.4%。相比之下，1994 年至 2003 年的资金增长速度为每年 7.8%（P<0.001）。2007 年，工业界（58%）是最大的资金来源，其次是联邦政府（33%）。资金的适度增长并没有伴随着药物或器械批准数量的增加。2007 年，美国在生物医学研究上的支出约占其总卫生支出的 4.5%，在卫生服务研究上的支出占 0.1%。
在经历了十年的翻番后，2003 年至 2007 年生物医学研究资金的增长速度放缓，按通胀调整后，2008 年国立卫生研究院和工业界的资金绝对水平似乎下降了 2%。
